Inventor · disambiguated record
Claudia Blümel
Also filed as: BLUEMEL CLAUDIA · BLUMEL CLAUDIA · BLÜMEL CLAUDIA
16 granted patents·11 pending applications·86 citations·filing 2009–2025
92Inventor score
Top patents by PatentIndex Score
27 records- 0197US10294300B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted May 21, 2019·37 cites·16 claims
- 0296US11591396B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2020·Granted Feb 28, 2023·5 cites·33 claims
- 0394US9765157B2Antibody constructs for CDH19 and CD3AMGEN INC·Filed 2015·Granted Sep 19, 2017·13 cites·14 claims
- 0493US10683351B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2019·Granted Jun 16, 2020·4 cites·24 claims
- 0591US11692031B2Antibody constructs for CLDN18.2 and CD3AMGEN RES MUNICH GMBH·Filed 2019·Granted Jul 4, 2023·6 cites·18 claims
- 0688US9260522B2Bispecific single chain antibodies with specificity for high molecular weight target antigensKUFER PETER·Filed 2009·Granted Feb 16, 2016·7 cites·4 claims
- 0786US11447567B2Antibody constructs for FLT3 and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted Sep 20, 2022·4 cites·18 claims
- 0884US12435139B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2022·Granted Oct 7, 2025·0 cites·12 claims
- 0983US10047159B2Bispecific single chain antibodies with specificity for high molecular weight target antigensAMGEN RES MUNICH GMBH·Filed 2016·Granted Aug 14, 2018·3 cites·18 claims
- 1083US2025340639A1Antibody constructs for dll3 and cd3AMGEN RES MUNICH GMBH·Filed 2025·Application pending·0 cites
- 1182US12297292B2Antibody constructs for CDH19 and CD3AMGEN INC·Filed 2017·Granted May 13, 2025·2 cites·12 claims
- 1282US10851170B2Antibody constructs for CD70 and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted Dec 1, 2020·3 cites·18 claims
- 1378US2024400673A1Antibody constructs for msln and cd3AMGEN RES MUNICH GMBH·Filed 2023·Application pending·0 cites
- 1476US12304952B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2021·Granted May 20, 2025·0 cites·16 claims
- 1576US2025092133A1Bispecific antibody constructs for cdh3 and cd3AMGEN RES MUNICH GMBH·Filed 2024·Application pending·0 cites
- 1674US11884720B2Antibody constructs for MSLN and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted Jan 30, 2024·1 cites·23 claims
- 1770US11028171B2Bispecific antibody constructs for CDH3 and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted Jun 8, 2021·1 cites·14 claims
- 1870US2024174745A1Antibody Constructs for CLDN18.2 and CD3AMGEN RES MUNICH GMBH·Filed 2023·Application pending·0 cites
- 1967US2025282863A1Antibody constructs for msln and cd3AMGEN RES MUNICH GMBH·Filed 2025·Application pending·0 cites
- 2066US11926666B2Bispecific antibody constructs for CDH3 and CD3AMGEN RES MUNICH GMBH·Filed 2021·Granted Mar 12, 2024·0 cites·22 claims
- 2166US2023272113A1Antibody constructs for flt3 and cd3AMGEN RES MUNICH GMBH·Filed 2022·Application pending·0 cites
- 2261US2020362039A1Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-1rxcd3 or fapalphaxcd3 bispecific single chain antibodyAMGEN RES MUNICH GMBH·Filed 2019·Application pending·0 cites
- 2361US2019040133A1Bispecific single chain antibodies with specificity for high molecular weight target antigensAMGEN RES MUNICH GMBH·Filed 2018·Application pending·0 cites
- 2459US2012034228A1CROSS-SPECIES-SPECIFIC PSCAxCD3, CD19xCD3, C-METxCD3, ENDOSIALINxCD3, EPCAMxCD3, IGF-1RxCD3 OR FAPALPHAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODYKUFER PETER·Filed 2009·Application pending·0 cites
- 2557US2021284748A1Antibody constructs for cd70 and cd3AMGEN RES MUNICH GMBH·Filed 2020·Application pending·0 cites
- 2655US2024209078A1Multitargeting bispecific antigen-binding molecules of increased selectivityAMGEN INC·Filed 2021·Application pending·0 cites
- 2747US12258404B2Bispecific antibody construct directed to MUC17 and CD3AMGEN INC·Filed 2018·Granted Mar 25, 2025·0 cites·19 claims
Join the waitlist — get patent alerts
Get an alert when Claudia Blümel files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →